Janie Zhang

Dr. Janie Zhang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in JCO Oncology Practice
Verified
Journal Article
Closed access
ISIbrahim Sahin
Ibrahim Sahin
JZJanie Zhang
Janie Zhang
TSTurcin Saridogan
Turcin Saridogan
VGVikram Gorantla
Vikram Gorantla
JRJohn Rhree
John Rhree
ASAnwaar Saeed
Anwaar Saeed
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm of mismatch repair–deficient/microsatellite instability-high (MMMR-D/MSI-H) colorectal cancer (CRC). Unique molecular features of MMR-D/MSI-H CRC with frameshift alterations, which result in mutation-associated neoantigen (MANA) generation, create an ideal molecular framework for MANA-driven T-cell priming and antitumor immunity. These biologic characteristics of MMR-D/MSI-H CRC resulted in rapid drug development with ICIs for patients with MMR-D/MSI-H CRC. Observed deep and durable responses with the use of ICIs in advanced-stage disease have stimulated the development of clinical trials with ICIs for patients with early-stage MMR-D/MSI-H CRC. Most recently, neoadjuvant dostarlimab monotherapy for nonoperative management of MMR-D/MSI-H rectal cancer and neoadjuvant NICHE trial with nivolumab and ipilimumab for MMR-D/MSI-H colon cancer resulted in groundbreaking results. Although nonoperative management of patients with MMR-D/MSI-H rectal cancer with ICIs will potentially define our current therapeutic approach, therapeutic goals of neoadjuvant ICI therapy for patients with MMR-D/MSI-H colon cancer may differ given that nonoperative management has not been well established for colon cancer. Herein, we overview recent advancements in ICI-based therapies for patients with early-stage MMR-D/MSI-H colon and rectal cancer and elaborate on the future treatment paradigm of this unique subgroup of CRC.

1 April 2022 in JCO Oncology Practice
Verified
Journal Article
Closed access
JZJanie Y. Zhang
Janie Y. Zhang
PKPamela L. Kunz
Pamela L. Kunz
Neuroendocrine tumors (NETs) are a heterogeneous clinical entity with a broad range of grade, pace of disease, functional status, and primary sites. Pathologic classification, diagnostic modalities, and therapeutic options for NETs have evolved considerably in the past decade. In part driven by these advances, incidence and prevalence of NETs are rising in the United States and the practicing oncologist is likely to encounter these in the clinic. However, there are no clear lines of therapy for unresectable or metastatic NETs, and sequencing of systemic therapies depends on consideration of patient and tumor characteristics including extent of disease, grade, pace of growth, functional status, primary site, somatostatin receptor status, performance status, and comorbidities. Familiarity with ongoing clinical trials will guide therapeutic decision making as well. In this review, we seek to provide a framework to formulate and tailor an individualized treatment plan for each patient with a NET.

18 December 2017 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
JZJanie Y. Zhang
Janie Y. Zhang
RBRobert Briski
Robert Briski
SDSumana Devata
Sumana Devata
MKMark S. Kaminski
Mark S. Kaminski
TPTycel J. Phillips
Tycel J. Phillips
RWRyan Wilcox
Ryan Wilcox

1 May 2015 in Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
MPMelanie E. Peffer
Melanie E. Peffer
JZJanie Y. Zhang
Janie Y. Zhang
LULeah Umfrey
Leah Umfrey
ARAnthony C. Rudine
Anthony C. Rudine
AMA. Paula Monaghan
A. Paula Monaghan
DDDonald B. DeFranco
Donald B. DeFranco
The life-threatening, emotional, and economic burdens of premature birth have been greatly alleviated by antenatal glucocorticoid (GC) treatment. Antenatal GCs accelerate tissue development reducing respiratory distress syndrome and intraventricular hemorrhage in premature infants. However, they can also alter developmental processes in the brain and trigger adverse behavioral and metabolic outcomes later in life. This review summarizes animal model and clinical studies that examined the impact of antenatal GCs on the developing brain. In addition, we describe studies that assess glucocorticoid receptor (GR) action in neural stem/progenitor cells (NSPCs) in vivo and in vitro. We highlight recent work from our group on two GR pathways that impact NSPC proliferation, ie, a nongenomic GR pathway that regulates gap junction intercellular communication between coupled NSPCs through site-specific phosphorylation of connexin 43 and a genomic pathway driven by differential promoter recruitment of a specific GR phosphoisoform.

1 October 2024 in JCO Oncology Practice
Verified
Journal Article
Closed access
ISIbrahim Sahin
Ibrahim Sahin
TSTurcin Saridogan
Turcin Saridogan
RARuveyda Ayasun
Ruveyda Ayasun
MSMasood Pasha Syed
Masood Pasha Syed
VGVikram Gorantla
Vikram Gorantla
ASAnwaar Saeed
Anwaar Saeed
KRAS mutations are common driver oncogenes associated with the development of several solid tumors. KRAS oncogene has been considered a highly challenging target for drug development because of structural features, including the lack of deep groove on its catalytic unit. However, by leveraging cysteine residues, covalent KRAS inhibitors irreversibly trap KRAS G12C mutants in their inactive GDP-bound state. These agents have resulted in significant clinical responses among patients with KRAS G12C-mutant solid tumors, including patients with colorectal cancer (CRC). Other allele-specific inhibitors of KRAS oncogene and panKRAS and panRAS inhibitors are also currently being investigated in clinical trials. This review article overviews recent clinical progress on KRAS G12C targeting for the management of patients with KRAS G12C-mutant CRC and provides an update on other RAS targeting approaches. We also discuss the unique biological features of RAS-mutant CRC, which require the combination of KRAS inhibitors and anti-epidermal growth factor receptor therapy, and elaborate on resistance mechanisms and novel therapeutic avenues that may define future treatment paradigms of patients with RAS-mutant CRC.

7 September 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
ACAKSHIT CHITKARA
AKSHIT CHITKARA
MBMuhammad Bakhtiar
Muhammad Bakhtiar
ISIbrahim Sahin
Ibrahim Sahin
DHDennis Hsu
Dennis Hsu
JZJanie Zhang
Janie Zhang
ASAnwaar Saeed
Anwaar Saeed
Recent trials provide evidence that HER2 is a potential new target for patients with colorectal cancer. While HER2-positive tumors do not show a very encouraging response to anti-HER2-positive agents like trastuzumab alone, promising results have been observed when combined with other synergistically acting tyrosine kinase inhibitors (TKIs). Our meta-analysis was conducted following the Cochrane Handbook and written following the PRISMA guidelines. The protocol was registered on PROSPERO with the registration number CRD42022338935. After a comprehensive search for relevant articles, 14 CTs were identified and uploaded to Rayyan, and six trials were ultimately selected for inclusion. The meta-analysis revealed that a median of three prior lines of therapy was used before enrolling in the six trials comprising 238 patients with HER2-positive metastatic colorectal cancer (mCRC). The pooled objective response rate (ORR) and disease control rate (DCR) were 31.33% (95% confidence interval [CI] 24.27–38.39) and 74.37% (95% CI 64.57–84.17), respectively. The pooled weighted progression-free survival (PFS) was 6.2 months. The pooled ORR and DCR meta-analysis indicate a significant response to HER2-targeted therapy in this patient in HER2-positive mCRC. Additionally, a pooled PFS of 6.2 months suggests that HER2-targeted treatment regimens are associated with a meaningful improvement in survival outcomes in this population.